Compare Stocks: APM, MDCX, COCP, and ADIL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$5.82 +7.8%	$3.46	$1.31 ▼ $10.75	$14.18M	1.39	88,575 shs	32,017 shs
APM Aptorum Group	$0.67 -4.6%	$5.04	$0.60 ▼ $4.47	$4.24M	0.38	57,956 shs	167,078 shs
COCP Cocrystal Pharma	$1.13 +1.8%	$1.01	$0.76 ▼ $2.67	$21.38M	1.43	86,880 shs	71,834 shs
MDCX Medicus Pharma	$0.26 +1.4%	$0.36	$0.24 ▼ $3.05	$16.26M	0.11	1.89 million shs	848,987 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	+7.78%	+6.79%	+109.35%	+143.51%	-39.34%
APM Aptorum Group	0.00%	0.00%	0.00%	-92.15%	-97.13%
COCP Cocrystal Pharma	+1.80%	+4.63%	+25.54%	+0.89%	-26.19%
MDCX Medicus Pharma	+1.40%	-0.87%	-29.46%	-15.40%	-87.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$5.82 +7.8%	$3.46	$1.31 ▼ $10.75	$14.18M	1.39	88,575 shs	32,017 shs
APM Aptorum Group	$0.67 -4.6%	$5.04	$0.60 ▼ $4.47	$4.24M	0.38	57,956 shs	167,078 shs
COCP Cocrystal Pharma	$1.13 +1.8%	$1.01	$0.76 ▼ $2.67	$21.38M	1.43	86,880 shs	71,834 shs
MDCX Medicus Pharma	$0.26 +1.4%	$0.36	$0.24 ▼ $3.05	$16.26M	0.11	1.89 million shs	848,987 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	+7.78%	+6.79%	+109.35%	+143.51%	-39.34%
APM Aptorum Group	0.00%	0.00%	0.00%	-92.15%	-97.13%
COCP Cocrystal Pharma	+1.80%	+4.63%	+25.54%	+0.89%	-26.19%
MDCX Medicus Pharma	+1.40%	-0.87%	-29.46%	-15.40%	-87.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	2.40	Hold	$15.63	168.47% Upside
APM Aptorum Group	1.00	Sell	N/A	N/A
COCP Cocrystal Pharma	1.00	Sell	N/A	N/A
MDCX Medicus Pharma	2.40	Hold	$9.00	3,348.28% Upside

Current Analyst Ratings Breakdown

Latest APM, MDCX, COCP, and ADIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	COCP Cocrystal Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	ADIL Adial Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
7/28/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
7/17/2026	ADIL Adial Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/16/2026	APM Aptorum Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	MDCX Medicus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/29/2026	APM Aptorum Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/15/2026	ADIL Adial Pharmaceuticals	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$6.00
6/15/2026	ADIL Adial Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy
6/11/2026	ADIL Adial Pharmaceuticals	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	($14.61) per share	N/A
APM Aptorum Group	$430K	9.86	N/A	N/A	$2.17 per share	0.31
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	$0.05 per share	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	($0.03) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$7.98M	-$14.73	N/A	N/A	N/A	N/A	-203.87%	-512.41%	N/A
APM Aptorum Group	-$1.36M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
COCP Cocrystal Pharma	-$8.83M	-$0.76	N/A	N/A	N/A	N/A	-207.47%	-123.33%	11/13/2026 (Estimated)
MDCX Medicus Pharma	-$35.46M	-$2.46	N/A	N/A	N/A	N/A	-3,137.84%	-263.24%	11/13/2026 (Estimated)

Latest APM, MDCX, COCP, and ADIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ADIL Adial Pharmaceuticals	-$1.0325	-$11.25	-$10.2175	-$11.25	N/A	N/A
8/13/2026	Q2 2026	COCP Cocrystal Pharma	-$0.17	-$0.23	-$0.06	-$0.23	$0.11 million	$0.11 million
8/12/2026	Q2 2026	MDCX Medicus Pharma	-$0.1275	-$0.21	-$0.0825	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	5.63	5.63
APM Aptorum Group	N/A	0.78	0.78
COCP Cocrystal Pharma	N/A	1.24	1.24
MDCX Medicus Pharma	N/A	1.57	1.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
APM Aptorum Group	3.80%
COCP Cocrystal Pharma	6.72%
MDCX Medicus Pharma	N/A

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	1.86%
APM Aptorum Group	63.99%
COCP Cocrystal Pharma	39.40%
MDCX Medicus Pharma	8.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	20	2.63 million	2.58 million	No Data
APM Aptorum Group	30	6.35 million	2.29 million	Not Optionable
COCP Cocrystal Pharma	10	19.26 million	11.67 million	Not Optionable
MDCX Medicus Pharma	N/A	63.18 million	58.06 million	N/A

APM, MDCX, COCP, and ADIL Headlines

Recent News About These Companies

Analysts Issue Forecasts for Medicus Pharma Q3 Earnings

August 20, 2026 | americanbankingnews.com

Analysts Set Expectations for Medicus Pharma FY2029 Earnings

August 17, 2026 | americanbankingnews.com

Medicus Pharma advances pipeline during Q2 with key milestones

August 13, 2026 | proactiveinvestors.com

Medicus Pharma advances pipeline during Q2 with key milestones

August 13, 2026 | proactiveinvestors.com

Medicus Pharma Advances SkinJect and Teverelix Amid Financing Gains and Going-Concern Risk

August 12, 2026 | tipranks.com

Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | accessnewswire.comA

Medicus Pharma CMO to lead Antev's Teverelix clinical programme

August 3, 2026 | proactiveinvestors.co.uk

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

August 3, 2026 | globenewswire.com

Medicus Pharma targets Gorlin Syndrome with SkinJect - ICYMI

August 1, 2026 | proactiveinvestors.com

Medicus Pharma Gets UAE Approval to Begin Phase 2 Endometriosis Drug trial

July 31, 2026 | finance.yahoo.com

Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix

July 31, 2026 | proactiveinvestors.com

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women ...

July 31, 2026 | markets.businessinsider.com

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

July 31, 2026 | globenewswire.com

Medicus Pharma Gets FDA Approval to Advance Phase 2b SkinJect Study

July 28, 2026 | finance.yahoo.com

Medicus Pharma cleared by FDA for registrational Phase 2b trial in patients with Gorlin Syndrome

July 27, 2026 | finance.yahoo.com

Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome

July 27, 2026 | markets.businessinsider.com

Medicus Pharma receives FDA clearance to begin registrational SkinJect study for Gorlin syndrome

July 27, 2026 | proactiveinvestors.com

Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome

July 27, 2026 | globenewswire.com

Medicus Pharma CEO details Teverelix progress – ICYMI

July 18, 2026 | proactiveinvestors.com

Medicus Pharma advances Phase 2 study following FDA and IRB feedback

July 18, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, MDCX, COCP, and ADIL Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

$5.82 +0.42 (+7.78%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$5.38 -0.44 (-7.49%)

As of 05:26 AM Eastern

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Aptorum Group NASDAQ:APM

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Cocrystal Pharma NASDAQ:COCP

$1.13 +0.02 (+1.80%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$1.13 0.00 (0.00%)

As of 08/25/2026 04:53 PM Eastern

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Medicus Pharma NASDAQ:MDCX

$0.26 +0.00 (+1.40%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$0.27 +0.01 (+4.98%)

As of 06:16 AM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APM, MDCX, COCP, and ADIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APM, MDCX, COCP, and ADIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APM, MDCX, COCP, and ADIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, MDCX, COCP, and ADIL Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

Aptorum Group NASDAQ:APM

Cocrystal Pharma NASDAQ:COCP

Medicus Pharma NASDAQ:MDCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APM, MDCX, COCP, and ADIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APM, MDCX, COCP, and ADIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APM, MDCX, COCP, and ADIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, MDCX, COCP, and ADIL Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

Aptorum Group NASDAQ:APM

Cocrystal Pharma NASDAQ:COCP

Medicus Pharma NASDAQ:MDCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools